AMNEAL PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $2.75 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-27
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $2.75, a 5.50% decline from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $2.91, a 5.82% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $2.75, a 0.00% change from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $2.75, a 0.36% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.75 10-K · filed 2026-02-27 | |||
| 2024-12-31 | $2.91 10-K · filed 2026-02-27 | |||
| 2023-12-31 | $2.75 10-K · filed 2026-02-27 | |||
| 2022-12-31 | $2.75 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $2.76 10-K · filed 2024-03-14 | |||
| 2020-12-31 | $2.75 10-K · filed 2023-03-03 | |||
| 2019-12-31 | $6.64 10-K · filed 2022-03-01 | |||
| 2019-11-14 | $2.75 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $10.80 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $11.36 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $12.06 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |